TRCT
TXG icon

Tower Research Capital (TRC)’s 10x Genomics TXG Stock Holding History

Tower Research Capital (TRC)’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Sell
5,432
-1,131
-17% -$22.6K ﹤0.01% 2071
2025
Q4 		$107K Sell
6,563
-48,771
-88% -$737K ﹤0.01% 1898
2025
Q3 		$647K Buy
55,334
+21,444
+63% +$280K 0.02% 711
2025
Q2 		$392K Sell
33,890
-6,586
-16% -$60K 0.01% 1183
2025
Q1 		$356K Buy
40,476
+9,712
+32% +$122K 0.01% 1044
2024
Q4 		$442K Buy
30,764
+26,565
+633% +$419K 0.01% 1156
2024
Q3 		$94.8K Buy
4,199
+977
+30% +$20.2K ﹤0.01% 2277
2024
Q2 		$62.7K Sell
3,222
-1,564
-33% -$41K ﹤0.01% 2925
2024
Q1 		$180K Buy
4,786
+1,636
+52% +$71.9K ﹤0.01% 1478
2023
Q4 		$176K Buy
3,150
+446
+16% +$19.4K ﹤0.01% 2204
2023
Q3 		$112K Sell
2,704
-4,058
-60% -$211K ﹤0.01% 1908
2023
Q2 		$378K Buy
6,762
+4
+0.1% +$216 0.01% 1152
2023
Q1 		$377K Buy
6,758
+3,856
+133% +$180K 0.01% 1005
2022
Q4 		$106K Sell
2,902
-16,445
-85% -$538K ﹤0.01% 1793
2022
Q3 		$551K Buy
19,347
+1,949
+11% +$74.3K 0.01% 1066
2022
Q2 		$788K Buy
17,398
+9,741
+127% +$505K 0.02% 835
2022
Q1 		$583K Buy
7,657
+3,620
+90% +$317K 0.01% 1070
2021
Q4 		$602K Buy
4,037
+1,422
+54% +$218K 0.01% 991
2021
Q3 		$380K Sell
2,615
-11,658
-82% -$2M 0.01% 1188
2021
Q2 		$2.79M Sell
14,273
-1,452
-9% -$263K 0.07% 209
2021
Q1 		$2.85M Buy
15,725
+12,179
+343% +$2.1M 0.05% 363
2020
Q4 		$502K Buy
3,546
+3,311
+1,409% +$480K 0.02% 989
2020
Q3 		$29K Sell
235
-648
-73% -$68K ﹤0.01% 3737
2020
Q2 		$79K Buy
+883
New +$68.8K ﹤0.01% 2662
2020
Q1 		– Sell
-5,263
Closed -$401K – 3907
2019
Q4 		$401K Buy
5,263
+311
+6% +$18.7K 0.03% 343
2019
Q3 		$250K Buy
+4,952
New +$274K 0.02% 892

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s TXG Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its 10x Genomics (TXG) stake by 17% in Q1 2026, selling an estimated $22.6K and leaving 5,432 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Tower Research Capital (TRC) first reported a position in TXG in Q3 2019 and has held it in 26 quarters since. The position peaked at $2.85M in Q1 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Tower Research Capital (TRC) held 5,432 shares of 10x Genomics worth $115K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,131 10x Genomics shares in Q1 2026, an estimated $22.6K.
  • 10x Genomics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2071 holding.
  • Tower Research Capital (TRC) first reported a position in 10x Genomics in Q3 2019 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s 10x Genomics position peaked at $2.85M in Q1 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.